Verizon IndyCar Series driver Pippa Mann will partner with Genetic Technologies Limited (NASDAQ: GENE), a molecular diagnostics company specializing in women’s health, in 2016 to promote BREVAGenplus®, the company’s first-in-class, clinically validated risk assessment test for non-hereditary breast cancer.
This new relationship between Pippa and Genetic Technologies further affirms Pippa’s commitment to breast cancer prevention and its associated technologies. Pippa is entering her third year of a partnership with Susan G. Komen®, the world’s largest breast cancer organization.
Driving the pink and white Susan G. Komen car in the past two Indianapolis 500 races, Pippa has raised awareness and funding to support the cause through her IndyCar activities. Pippa is an ambassador for women’s health with several organizations and is active both nationally and locally in her support of Komen.
“I am thrilled to be able to represent another group that is committed to helping end breast cancer by partnering with Genetic Technologies,” said Pippa. “It is fantastic to be able to represent such a game-changing product in the women’s health space. I am looking forward to helping raise the profile of BREVAGenplus® through the exposure that comes with IndyCar and the Indianapolis 500.”
The associate sponsorship agreement between Pippa and Genetic Technologies will consist of apparel representation, participation at BREVAGenplus® oriented events and speaking engagements, social media, print and video campaigns, and related sales support activities. Pippa plans to use this new partnership in the 100th running of the Indianapolis 500 on May 29, 2016.
About Genetic Technologies Limited
Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women’s health. The Company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus® improves upon the predictive power of the first generation BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGenplus® expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer. The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGenplus®, launched in October 2014, significantly expands the applicable market. The Company markets BREVAGenplus® to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons). For more information, please visitwww.brevagenplus.com and www.phenogensciences.com.
